Endotension after endovascular aneurysm repair: The Ancure experience  by Meier, George H. et al.
applied to the aneurysm sac, independent of the presence
or absence of endoleak, remain poorly defined. Although
some endoleaks certainly expose the aneurysm sac to sys-
temic pressures and pulsatility, many endoleaks appear to
moderate the hemodynamic forces applied to the aneurysm
sac and limit aneurysm expansion. In fact, aneurysm con-
traction is common after endovascular aneurysm repair,
despite persistent endoleak. Nevertheless, although conser-
vative management of Type II endoleaks is an accepted
approach clinically, Type I endoleaks should be repaired as
a routine.
Perhaps the most poorly defined of the forces applied
to the residual aneurysm sac is that termed endotension,3
defined as aneurysm expansion in the absence of
detectable endoleak. This entity has been associated with
not only aneurysm expansion but also aneurysm rupture.4
Unfortunately, there is no definitive test to rule out the
presence or absence of endoleak; an undetected endoleak
remains a distinct possibility as the hidden cause of most
endotension. Therefore, the nature of endotension and
the circumstance under which it can occur are ill defined
at best. Additionally, the changes in the aneurysm wall
metalloprotease and collagenase activity after endovascular
repair are not defined or understood. 
This review of the independent core laboratory imag-
ing data from the Guidant Ancure endograft Phase I and
Phase II trials was undertaken to see if endotension could
The ultimate determinant of successful abdominal aor-
tic aneurysm (AAA) management is the absence of
aneurysm expansion and rupture. Any therapy that limits
aneurysm expansion can be deemed successful, whether
pharmacologic or mechanical. Newer techniques of
endovascular aneurysm grafting are now being evaluated
against this standard to find an alternative to open surgery
for AAA. The success of these techniques must be ulti-
mately judged by their ability to limit aneurysm growth. 
The early experience with endovascular aneurysm
repair has demonstrated a high incidence of residual
aneurysm blood flow outside the endograft,1,2 termed
endoleak. This flow carries a blood pressure that potentially
maintains aneurysm expansion. Despite this concern, most
endovascular aneurysm repairs with endoleak continue to
shrink despite this residual blood flow,1 a fact that remains
controversial. Nevertheless, the exact hemodynamic forces
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Purpose: The expansion of aneurysms after endovascular repair is a consequence of persistent sac pressure, usually result-
ing from an endoleak. Several authors have suggested that sac expansion can occur even in the absence of endoleak,
referring to this phenomenon as endotension. This study undertakes a review of the largest US endograft trial data to
better define the significance of aneurysm expansion in the absence of endoleak.
Methods: The core laboratory imaging database from the Ancure (Guidant) endovascular graft Phase I and Phase II tri-
als approved by the Food and Drug Administration was reviewed with attention to aneurysm size and endoleak.
Aneurysm size was measured with standardized two-dimensional computed tomography (CT) scan at the area of largest
initial aneurysm diameter. Endoleak was detected with CT scans, color duplex ultrasound scans, and angiography in
selected cases. Patients were evaluated at baseline, 3 months, 6 months, 12 months, and every 12 months thereafter.
An endograft was classified as leaking if any endoleak was detected with any modality at any time point. 
Results: A total of 658 patients were entered into these protocols and the data submitted to the core laboratory. A con-
trol group of 120 conventional aortic patients and a group of 62 without baseline CT data were excluded from further
analysis. Of the remaining 476 patients, 144 (60 tube, 60 bifurcated, and 24 mono-iliac) were free of endoleak at all
intervals and had baseline CT measurements to allow comparison. Overall, the average size decrease in this nonleaking
group was 9.9 ± 9.4 mm (range, –50.6-11.1 mm) at a mean follow-up of 23.3 months. Evaluation for overall aneurysm
expansion revealed 17 patients who had an increase of 2.3 ± 2.9 mm (range, 0.3-11.1 mm) at a mean follow-up of 14.1
months. Only two patients without evidence of endoleak exhibited growth of more than 5 mm at maximum follow-up
(7.6 mm at 12 months and 11.1 mm at 36 months). Additional analysis of sealed endoleaks and late endoleaks failed
to demonstrate any group with expansion in the absence of detectable endoleak. 
Conclusions: Endotension appears to be rare in this large series of prospectively evaluated endografts. From this review,
endotension seems more likely to represent missed endoleak than true aneurysm expansion in the absence of perigraft
flow. (J Vasc Surg 2001;34:421-7.)
be detected. This large, prospective endograft cohort
underwent standardized imaging with independent classi-
fication for endoleak and size, providing the best possibil-
ity for detection of endotension if it were to occur.
METHODS
The records of the Phase I and Phase II trial approved
by the Food and Drug Administration for the Guidant
(EVT) Ancure endograft were used as the source for patients
reviewed for this study. The Ancure endovascular stent graft
was first evaluated under Food and Drug Administration
protocol in 1991. A total of 33 sites were used for these
Phase I and Phase II protocols between May 1993 and
December 1998. Each Institutional Review Board reviewed
the experimental protocol, and consent forms and informed
consent were obtained from all patients. The imaging data
for all patients were reviewed, measured, and classified at an
independent central core laboratory facility at the Cleveland
Clinic. These independently reviewed core laboratory data
are the source for this analysis.
Computed tomography (CT) scans, color duplex
ultrasound (CDU) scans, and plain x-ray films were per-
formed according to protocol5 at baseline, 3 months, 6
months, 12 months, and every 12 months thereafter.
Angiography was occasionally performed as well, when
clinically indicated. CT scans were done with 3-mm cuts
on a spiral CT scanner with bolus intravenous contrast and
delayed imaging. The CT scans and ultrasound examina-
tions were measured for aortic, iliac, and graft diameters;
similarly, both methods were also used for detection of
perigraft flow (endoleak) and limb dysfunction. Aneurysm
diameter was assessed at the same level with CT scans; the
major axis diameter, the minor axis diameter, and the
cross-sectional area were measured at this reference level.
Minor axis diameter and cross-sectional area were used to
help control for tortuosity. In analysis of the data, all three
measures were independently analyzed. For the purposes
of this article, no differences were seen in the data on the
basis of the use of these parameters. Therefore, the major
axis diameter was thought to be the best measure for
reporting and will be the sole measure reported here.
Ultrasound measurements were made at the greatest
aneurysm diameter, measuring both major axis and minor
axis diameters. Again, no differences were seen on the
basis of the analysis by these two parameters, and there-
fore, major axis ultrasound diameter was used where
appropriate for analysis.
The presence of endoleak was determined by these
studies and labeled as none, attachment site, branch flow,
or transaneurysmal (leak at both the proximal and distal
attachments). If the studies could not isolate the site of leak
but flow was clearly seen, the grafts were recorded as
source unknown. If endoleak was seen on any study with
any modality at any time point, the graft was labeled as
leaking. This results in a relatively high endoleak rate
because of the inclusion of many isolated, clinically
insignificant endoleaks. Nevertheless, no attempt was made
to define the clinical significance of any endoleak reported
by the core laboratory. The endoleak rate reported here is
therefore a maximum endoleak rate for this population.
A total of 658 patients were entered into these trials.6
Of these, 120 patients served as conventionally operated
controls and therefore cannot be further analyzed, leaving
538 patients for this review. Of these patients, 62 could
not be evaluated for AAA size changes, leaving 476 for
analysis of aneurysm size and endoleak.
For the analysis of endotension, three groups were
thought to be necessary. Group I comprised those patients
who never had any evidence of endoleak at any time with
any modality. These patients were the most likely to be
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Fig 1. Overall data series for this study (N = 476). The x-axis represents maximum follow-up with over-
all aneurysm size change on y-axis. Solid line represents linear regression fit to data.
free of occult endoleak and represent the purest group of
nonleaking patients. If endotension were sporadic and
independent of endoleak, then this group would be the
most likely to harbor endotension. Group II patients were
those at risk for endotension because of a sealed endoleak.
All of the patients who had a baseline leak that was sealed
at all subsequent time points were counted in this group.
The transmission of pressure through a sealed endoleak is
one of the leading explanations for endotension if it
occurs.7 The final group, Group III, comprised those
patients whose endotension may have led to endoleak
later, namely, those who had no endoleak at baseline and
6 months but had endoleak later. If significant size
increases occurred before the development of endoleak,
then these patients could possibly harbor endotension and
may have been lost from analysis because of the later
development of endoleak.
Statistical analysis was performed with commercial
software for statistical analysis (Systat, Version 10; SPSS,
Inc, Chicago, Ill). A P value less than .05 was considered
statistically significant. Linear regression was done for
analysis of graphical data.
RESULTS
Overall, 476 ancure endograft patients underwent
core laboratory measurement of aneurysm size at baseline
and at least one point in follow-up. The mean follow-up
for this group was 23.2 months (range, 2.0-78.8 months).
The baseline major axis aneurysm size measured from
34.8 mm to 92.7 mm with a mean of 57.5 ± 9.9 mm.
Minor axis diameter, defined as the smallest AAA diameter
at the level of the maximum diameter (an indirect measure
of aneurysm roundness), was 30.9 to 86.4 mm with a
mean of 51.6 ± 9.2 mm. The aneurysm area at the level of
maximum aneurysm diameter was 2395 ± 838 mm2. In
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this overall group, the rate of overall aneurysm contraction
ranged from –50.6 to 32.6 mm with a mean of –7.3 ± 9.2
mm at 23.2 months’ follow-up (–3.75 mm/y). The over-
all change in major aneurysm diameter versus the follow-
up interval for the entire series is seen in Fig 1. Similar
trends were seen for both minor axis diameter and cross-
sectional area as well.
In Group I (never leaking), 144 patients had complete
exclusion of endoleak with both CT scan and CDU scan
at all time points. Baseline aneurysm size measured 55.2 ±
9.6 mm (range, 38.9-88.3 mm). Overall aneurysm size
change was –10.0 ± 9.5 mm at a mean follow-up of 23.2
months (annualized change = –5.15 mm/y). Of these
patients, 17 had an overall increase in aneurysm size in fol-
low-up (mean, 2.3 ± 2.9 mm; range, 0.3-11.1 mm). Of
these with an overall increase, only two patients exhibited
an increase greater than 5 mm (7.6 mm at 12.0 months
and 11.1 mm at 36.0 months). In the first case a noncon-
trast CT scan was performed for the 6-month check, mak-
ing the possibility of occult endoleak real. In the second
case, all CT scans were performed with contrast, but the
last two CDU scan examinations were indeterminate for
endoleak. The overall data for this group are seen in Fig 2.
If endotension results from transmission from a
sealed endoleak, then a high-risk group for endotension
would be that group of patients who had initial endoleak,
but sealed spontaneously (Group II). In the overall
group 78 patients fulfilled this criterion of an initial,
baseline endoleak that was never seen again in follow-up.
In these 78 patients, the baseline aneurysm size was 58.6
± 8.2 mm (range, 41.5-80.5 mm). Overall change in
aneurysm size was –8.9 ± 6.9 mm at a mean follow-up of
18.5 months (annualized rate = –5.8 mm/y). Only five
patients had an overall increase in aneurysm size in this
group, for a mean change of 1.5 ± 1.9 mm at 19.0
Fig 2. Net change in aneurysm size versus maximum follow-up for all patients who never exhibited any
endoleak at any time point (N = 144). Solid line represents linear regression fit to data.
months’ follow-up (annualized rate = 1.0 mm/y; range,
0.2-4.9 mm). Only one patient had a net increase in
aneurysm size of more than 3 mm (4.9 mm at 29.3
months). Thus, endotension from sealed endoleak does
not appear to occur in this series because the largest
increase in aneurysm size was about 2 mm/y in the
absence of ongoing endoleak (Fig 3).
The final group of patients in whom endotension
might be active would be those without initial endoleak
whose aneurysm sac expansion led to overt endoleak later.
For this reason, all of the patients without leaking at base-
line and 6 months were evaluated for subsequent endoleak.
A total of 185 patients met this requirement. Of these, 41
had late endoleak at 12 months or after. Initial aneurysm
diameters were 56.7 ± 9.9 mm (range, 34.8-77.3 mm).
These patients exhibited a wide range of aneurysm size
changes, ranging from –18.8 to 32.6 mm (mean, –3.3 ±
9.4 mm; annualized rate, –1.4 mm/y) at a mean follow-up
of 28.2 months (Fig 4). Fourteen patients had net positive
aneurysm size changes, including three with size changes
greater than 5 mm. In all three of these patients, most of
the expansion occurred after the development of endoleak,
with minimal expansion in the initial phases when endoleak
was absent. Therefore, the endoleak appears to explain the
aneurysm size changes, rather than aneurysm size changes
occurring in the absence of endoleak.
DISCUSSION
Endovascular repair of AAAs is rapidly becoming an
accepted alternative to conventional open aortic aneurysm
repair. Despite this change, numerous problems can occur
with this new procedure that were never an issue in con-
ventional surgery.8-10 Foremost among these is endoleak,
the presence of intra-aneurysm perigraft flow around a
functioning endovascular graft. Although the causes of
endoleak are many, any exposure of the residual aneurysm
sac to arterial flow represents a potential for aneurysm
expansion and even rupture.
Obviously, a failure to exclude the aneurysm sac from
flow in most instances represents a persistent pressuriza-
tion of the aneurysm. Despite persistent endoleak, most
aneurysms still contract over time, suggesting that the true
hemodynamic force on the residual aneurysm sac is less
than what was present before endograft placement. With
this contraction, endoleak should disappear as the residual
aneurysm sac regresses, although the natural history of
endoleak remains poorly defined. If no endoleak is
detectable, then the aneurysm should be maximally pro-
tected and risk of expansion or rupture minimized.
In about 1996, the Sydney group began to support
the concept of endotension, defined as the expansion of an
AAA in the absence of endoleak.4 The forces responsible
for this expansion remain unclear, but any expansion sug-
gests persistent pressurization of the residual aneurysm
sac.11,12 The difficulty in this lies in completely excluding
any endoleak. Many observers think that endotension sim-
ply represented missed endoleak,13 because the techniques
for endoleak detection remain variable and less than cer-
tain.5,14 Nevertheless, the possibility that aneurysm expan-
sion can occur without an endoleak remains at the core of
the endotension discussion.
A standardized, prospective population in whom
endoleak detection has been shown to be high was used in
this study.5 Because of this, the possibility of false-negative
study results is minimized if the detection rate is high.
Second, this group represents the largest endograft popu-
lation available with complete adjudication of the imaging
data by an independent core laboratory. This independent
assessment standardizes the criteria for endoleak and man-
dates that all images submitted are standardized in their
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Fig 3. Net change in aneurysm size versus maximum follow-up for all patients who exhibited initial endoleak
but no subsequent leak at any later time point (N = 78). Solid line represents linear regression fit to data.
review. Therefore, this data set provides a population with
a high endoleak detection rate, where exclusion of
endoleak is likely to provide a highly specific group with-
out contamination by occult, undetected endoleak.
Although this is the highest reported rate of endoleak in
the literature, we view this high endoleak rate as a maxi-
mum rate and not the clinically expected rate of leak for a
given patient. We would discourage the use of this
endoleak rate as a clinical gauge of outcome, nor do we
expect this endoleak rate in our patients in follow-up.
The weaknesses of these data, however, lie in their dis-
connection from clinical care and clinical events. Only lim-
ited data are available about interventions in these
patients, and these data are incomplete. An absence of data
submission may represent an oversight by the center or a
major adverse patient event unknown to the independent
core laboratory. Although the ideal data set for this analy-
sis combines both adverse event data and the core labora-
tory data, these paired data are currently unavailable.
Three groups were analyzed for the possibility of
endotension: never-leaking grafts with at least 6 months’
follow-up; initially leaking grafts with subsequent seal for
the remainder of follow-up; and finally, late endoleaks
where expanding aneurysms may have led to endoleaks
secondarily. These groups represent subpopulations in
whom endotension may have played a role and were there-
fore subjected to analysis. 
The purest group of patients in whom endotension
would be expected is that group in whom endoleak
never occurred. If endoleak has nothing to do with
endotension, then this group would be expected to
demonstrate expansion if endotension occurred. Of the
144 patients without any endoleak in follow-up, only 17
patients demonstrated expansion in follow-up, and only
2 had expansion of more that 5 mm overall (7.6 mm at
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1 year and 11.1 mm at 3 years). Although these may
represent endotension, they are just as likely to represent
undetectable endoleak as an explanation.
The second group analyzed represents that group
invoked by previous experimental and clinical observations,
namely, patients with sealed endoleaks. Experimental stud-
ies have demonstrated that pressure can be transmitted
through sealed endoleaks.7,15 Although our view is that
any clot that would transmit pressure is dynamic rather
than static (and therefore likely to recanalize), this group
looks specifically at those patients with initial endoleak and
no further endoleak in follow-up. A total of 78 patients had
size measurements on the follow-up CT scans to allow
assessment of overall aneurysm size changes. Of these 78,
the average size change was –4.8 mm/y at a mean follow-
up of 22.5 months. In only five patients did the aneurysm
size expand: 0.4 mm at 6.0 months, 0.2 mm at 11.5
months, 0.9 mm at 12.2 months, 1.2 mm at 36.1 months,
and 4.9 mm at 29.3 months. Given these changes, we
think that it is unlikely that clot transmission of pressure
into the residual aneurysm sac occurs.
The final group of patients in whom we envisioned
endotension to be active was the group without initial
endoleak, but in whom late endoleak developed. The late
appearance of endoleak after 6 months could possibly
obscure a patient with endotension early in follow-up,
which may have led to the development of endoleak as
the aneurysm sac expanded. A total of 41 patients had
adequate baseline and follow-up CT data for AAA size.
Of these, only 14 patients had expansion, averaging 5.6
mm at 29.5 months’ follow-up (2.6 mm/y). In no case
was significant expansion (> 5 mm) seen before endoleak
development.
Given these data, our view is that endotension is rare
if, indeed, it does occur. Although no data exist to prove
Fig 4. Net change in aneurysm size versus maximum follow-up for all patients who had no endoleak at
baseline or 6 months but then had endoleak later (N = 31). Solid line represents linear regression fit to data.
this conclusion, we think that endotension most likely rep-
resents occult endoleak rather that unexplained expansion
in the absence of endoleak. We think that systematic inter-
rogation with both CT scan and CDU scan, as was the
Ancure protocol, maximizes endoleak rates because of
improved detection. Similarly, this increased detection
allows a search for endotension to better exclude occult
endoleak as a source for aneurysm sac expansion, mas-
querading as endotension. If endotension occurred in this
series, its incidence is low and not yet apparent. In our
view, endotension represents occult endoleak rather than a
new physical entity as yet undefined.
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DISCUSSION
Dr W. Anthony Lee (Gainesville, Fla). Good morning, Dr
Archie, Dr Eidt, Dr Seeger, members and guests. I would like to
thank the program committee for allowing me the opportunity to
discuss this paper and the authors for delivering the manuscript in
a timely fashion.
The Norfolk group has once again demonstrated their excel-
lence in clinical research by tackling the controversial topic of
endotension, which has been the subject of many recent debates.
Endotension is a term that was proposed to describe the phenom-
enon of aneurysm expansion following endovascular aneurysm
repair, both in the presence and absence of an endoleak, and in
point of fact, two of the three grades of endotension specifically
apply to aneurysms with endoleaks. In its original description by
Gilling-Smith from Liverpool, endotension was defined as the
persistent or recurrent pressurization of the aneurysm sac follow-
ing endovascular repair. More specifically, no direct or indirect
mechanistic or cause-and-effect relationship was implied or
intended between endoleak and pressure. Indeed, he, like many
others, sought to specifically discount much of the overstated
prognostic significance given to endoleaks and sought to draw
our attention back to the one and only certain prognostic marker
of any significance, which is that of aneurysm enlargement. 
In their presentation and manuscript, Dr Meier and col-
leagues have studied a large prospective database from the core
lab of the Guidant Ancure endograft phase I and II US clinical 
trials. By comparing the diameter changes of endografted
aneurysms in three subsets of patients, first, those who never had
endoleaks on either CT or color flow duplex; second, those who
had early endoleaks but which eventually sealed; and third, those
who did not have endoleaks initially but later developed on, they
have attempted to show that endotension is simply an occult
endoleak that is being missed by currently available imaging
modalities. The crux of their analyses lies in the reliability and
completeness of the core lab data. To this end, I would like to
address the following questions to the authors:
For the CT scans submitted to the core lab, did they include
all of the images required for a complete study, including a pre-
contrast, timed-bolus contrast, and delayed postcontrast phases?
It is well recognized that areas of intrasaccular high attenuation
that can sometimes be mistaken for an endoleak can only be
resolved by examination of the precontrast images. Conversely,
low-flow leaks are sometimes missed on the contrast images and
only seen on the delayed series.
Change in aneurysm size occurs in three dimensions, and
many have advocated volumetric analysis over simple diameter
measurements. Indeed, in a paper recently submitted to the
Journal of Vascular Surgery, we examined concurrent data triplets
of volume, greatest orthonormal cross-sectional area, and diame-
ter of aneurysms following endograft repair, and found that vol-
ume demonstrated the tightest fit on regression analysis, followed
by cross-sectional area, and lastly diameter. In your manuscript a
brief mention of size based on cross-sectional area was made. Why
was this not carried out for the rest of your data analysis?
Finally, of the 410 patients who were included in the three
subset analyses, 36 or 8.7% had increases in their aneurysm size.
When you break this number down, in Group 1 there were 17
patients or 12% who increased in size, in Group 2 there were 17
patients or 12% who increased in size, and in Group 3 there were
14 patients or 7%. Given the fact that there is almost twice the
incidence of increasing aneurysm size in the “never-had-an-
endoleak” group, does this not argue for (not against) the pres-
ence of endotension? 
In conclusion, I do not think that there is any dispute that the
meaning and concept of endotension are limited and its nature
and cause ill defined for the present. Analogies such as this abound
in the history of science, where a term is conceived to explain a
condition or an observation, whose cause must exist by the very
law of nature, but cannot be proven at the time of its conception
because of limitations of technology. Despite this, however, I
believe that endotension still serves to provide a useful, working
term to describe a phenomenon that, in the very near future, we
will and we must understand and clarify, if endovascular aneurysm
repair is to remain a viable alternative to open surgery. Indeed, we
and others are in the process of investigating potential methods of
measuring intrasaccular pressure noninvasively in order to better
understand endotension. I have very much enjoyed the excellent
presentation and the well-written manuscript and would highly
recommend it for publication by the Journal.
Dr George Meier. We agree that the definition of endotension
is a little bit fuzzy, and indeed at the recent Veith Consensus
Conference on Endoleak, a slight majority viewed endotension as
being usually associated with an endoleak, so I think that most
people believe that endotension and endoleak equal a pressurized
sac. The problem is its application, and many people, particularly
the Australian group, Jim May and Geoff White, have really
talked about endotension as being an expansion of the aneurysm
in the absence of endoleak and that is really the direction that
most have gone. I agree the definition is still very fuzzy. I think
that its use should be questioned, honestly.
Second, the issue of completeness of a CT scan. The core lab
gets what the core lab gets, and many of you have sent in data to
the core lab and you miss one or two films, and those may be the
critical films for size in an aneurysm or they may be the critical
films where endoleak might have been detected. The prescans
may be absent. There are a wide variety of data. The data are what
the data are, and in the majority of these cases, having looked at
the core lab data over several years, I can assure you that it is usu-
ally a complete CT scan. It is a very difficult thing to maintain
completeness when you have thousands and thousands of images
as they do.
The next question related to the volume effects and the area
effects. It turns out the area effects do not make any difference.
We have analyzed these data by major axis diameter, minor axis
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diameter, and area, and there is no difference in the analysis. For
that reason, we felt that getting into area or minor axis diameter
changes did not really add anything to the overall manuscript, and
since we measure aneurysms normally by their major axis diame-
ter we felt that was obviously something that was familiar to us all.
We would love to be able to measure volumes. We do not have
the continuous data sets in the core lab so we cannot look at vol-
umes in the core lab data, but obviously volume would be some-
thing that would be interesting to assess. In our hands, volume
takes some postprocessing time and a lot of effort. We do not do
it routinely; perhaps we should, but at this point we view it as a
research tool.
Finally, about the 36 patients that increased, I would argue
that a 2-mm increase is probably within the error of measuring
from one exam to the next and the error in measuring from one
observer to the next. Therefore, that 2-mm size change to us was
insignificant, so we felt those aneurysms were really static. There
are going to be some static aneurysms. We really looked at
aneurysms that were expanding significantly, and since the aver-
age rate of aneurysm expansion is 4 mm per year, we looked at
aneurysms that were two or three times that rate of expansion, the
highest rate being in the latter group that we presented where the
expansion rate was 10 mm a year at the highest rate of expansion.
I think when you are talking about 10 mm a year, you are talking
about the endotension realm. When you are talking about 1 mm,
you are talking about error of measurement and that is why we
did not count those in the endotension group. Could some of
those expand later? I think yes.
Dr William H. Edwards, Jr (Nashville, Tenn). Micky, I
enjoyed your presentation. It confirms my own thoughts about
endotension. I rise to provide a little bit of follow-up. A lot of us
here have submitted patients to the core lab, and they lag pretty
far behind what is really happening. We have had one patient in
the trial who had no detectable endoleak on multiple CT scans,
but had an increase in the size of his aneurysm, and eventually
came to angiography to try to decide what to do with the patient.
He in fact did have an endoleak. We sealed the endoleak, and now
6 months later his aneurysm is shrinking. In my opinion,
endotension is missed endoleaks.
Dr Meier. Thanks very much for your comments. We are com-
mitted to that theory as you can tell from our presentation and
indeed the core lab data do lag, but I think this is the best data
set we have available for this analysis. I thank the society.
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